Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618194 | 1.00 | ALDH1A1 (0.49) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL695876 | 0.90 | ALDH1A1 (0.46) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL27778093 | 0.87 | ALDH1A1 (0.47) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL14021283 | 0.85 | ALDH1A1 (0.50) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL2015323 | 0.85 | ALDH1A1 (0.57) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL19205982 | 0.83 | ALDH1A1 (0.49) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL28664477 | 0.83 | ALDH1A1 (0.49) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL28012388 | 0.83 | ALDH1A1 (0.46) | ALDH1A1POLBPDE7AMAPK1MEN1 | |
| SCHEMBL15068693 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPK1MEN1KMT2AMAPT | |
| SCHEMBL27651645 | 0.81 | ALDH1A1 (0.47) | ALDH1A1POLBPDE7AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103044432-B | Bicyclic heteroaryl compounds | 阿里亚德医药股份有限公司 | 2016-08-03 | — | — | CN | claimed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-20130178622-A1 | Methods and Compositions for Treating Cancer | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | claimed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250177382-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-3584239-B1 | O-AMINOHETEROARYL ALKYNYL-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-1973545-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007133562-A2 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133560-A2 | ACETYLENIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1840122-A1 | AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | Sun, Piaoyang (CN) | 2007-10-03 | — | — | EP | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| WO-2007075869-A2 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060241149-A1 | Chemical compounds | ADAMS JERRY L | 2006-10-26 | — | — | US | disclosed |
| EP-1581514-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043379-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | CHKB, MAP3K20, MAP3K6 | ALDH1A1 1938/4885POLB 2576/4885PDE7A 617/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | ALDH1A1 636/4885POLB 1974/4885PDE7A 4323/4885 |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | ALDH1A1 3063/4885POLB 1777/4885PDE7A 4450/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | ALDH1A1 3078/4885POLB 1704/4885PDE7A 4511/4885 |
| US-20250177382-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | ALDH1A1 3958/4885POLB 4015/4885PDE7A 260/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | ALDH1A1 4225/4885POLB 4139/4885PDE7A 301/4885 |
| US-20130178622-A1 | Methods and Compositions for Treating Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MKI67 | ALDH1A1 416/4885POLB 334/4885PDE7A 2596/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ALDH1A1 636/4885POLB 1974/4885PDE7A 4323/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | ALDH1A1 980/4885POLB 2407/4885PDE7A 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.